Signs That Keytruda Is Working: An Evidence-Based Guide for Patients

Signs that Keytruda is working are most reliably shown through follow-up imaging, physical examinations, and sometimes blood tests—not by how a person feels on a given day. A response may mean that cancer has shrunk, stopped growing, or is growing more slowly, and the timing varies widely by cancer type and individual circumstances.

What are the signs that Keytruda is working?

Signs that Keytruda is working are usually confirmed by scheduled scans and an oncologist’s assessment rather than symptoms alone. The clearest evidence is that tumors have become smaller, have not grown, or that no new cancer areas are seen on imaging. For some people, a meaningful result is stable disease: the cancer is not shrinking substantially, but it is also not progressing.

Keytruda is the brand name for pembrolizumab, an immunotherapy medicine called an immune checkpoint inhibitor. It helps the immune system recognize and attack certain cancer cells. It is used for several cancers, including some forms of melanoma, lung cancer, head and neck cancer, bladder cancer, kidney cancer, colorectal cancer, cervical cancer, and others. Whether it is appropriate depends on the cancer type, stage, previous treatments, and tumor testing.

A person may notice practical improvements, such as less cancer-related pain, improved appetite, more energy, reduced cough, or easier breathing. These changes can be important to share with the care team, but they are not a substitute for imaging. Symptoms can improve for reasons unrelated to tumor response, and some cancers can grow without causing new symptoms.

How doctors measure a response to Keytruda

Before treatment begins, the oncology team establishes a baseline. This may include CT, MRI, PET-CT, or other imaging; a physical examination; blood tests; and a discussion of symptoms and daily functioning. Future results are compared with this baseline to determine whether the cancer is responding.

Follow-up scans are commonly performed after several treatment cycles, although the exact schedule depends on the cancer and treatment plan. Radiologists and oncologists assess the size of known tumors, look for new lesions, and consider changes in lymph nodes or organs affected by cancer. A scan may show a complete response, partial response, stable disease, or progression.

Blood tests may also support monitoring. Depending on the situation, clinicians may follow blood counts, liver and kidney function, thyroid levels, and selected tumor markers. Tumor markers can be useful in some cancers, but they do not provide a complete answer on their own. Results are interpreted alongside scans, symptoms, and examination findings.

The care team also considers overall function. Being able to walk farther, carry out more daily activities, sleep better, or require less pain medicine can reflect clinical benefit. However, decisions about continuing, changing, or pausing treatment should be made with the oncology team using the full clinical picture.

Response patterns: shrinkage is not the only positive result

Many people expect an effective cancer treatment to make tumors disappear quickly. With Keytruda, responses can be more gradual. Tumors may shrink after the first few months, remain unchanged for a period, or continue to reduce in size over later scans. A stable scan can be a favorable outcome when the treatment is preventing further cancer growth.

In a smaller number of patients, immunotherapy can produce an early scan appearance called pseudoprogression. Immune cells entering a tumor may temporarily make it look larger or more inflamed before it later becomes smaller. This is less common than true cancer progression, so it should never be assumed without careful evaluation. The oncology team may recommend repeat imaging or other assessments when the person is clinically stable and the findings are uncertain.

Occasionally, one tumor area may grow while other areas shrink or remain stable. This mixed response requires individualized planning. Depending on the cancer, its location, symptoms, and the extent of change, clinicians may continue immunotherapy, treat a limited progressing site with a local approach, or consider another systemic treatment.

Keytruda does not work for every patient, even when tumor testing suggests that it may help. A lack of response is not caused by something a patient did or did not do. Cancer behavior and immune response are complex, and treatment decisions are adjusted as new information becomes available.

Symptoms that may improve—and what they can and cannot mean

If cancer-related symptoms were present before treatment, improvement may be encouraging. For example, a person with lung cancer may have less cough, chest discomfort, breathlessness, or fatigue. Someone treated for another cancer may notice less pain, less bleeding, improved swallowing, better appetite, or fewer pressure-related symptoms.

However, feeling tired, having a poor appetite, or experiencing pain during treatment does not automatically mean Keytruda has failed. These symptoms may result from the cancer itself, anemia, infection, sleep disruption, emotional stress, other medicines, or treatment side effects. Likewise, feeling well does not always mean the cancer is controlled, particularly if the cancer was not causing symptoms initially.

Keeping a simple symptom record can help. Patients can note new symptoms, their severity, when they began, what improves or worsens them, and how they affect daily life. This gives the oncology team useful information between scan appointments and can help identify side effects early.

It is particularly important not to wait for the next scheduled visit if symptoms are severe, sudden, or worsening. Prompt communication can protect health and may allow side effects to be treated before they become more serious.

Do Keytruda side effects mean it is working?

No. Side effects are not a reliable sign that Keytruda is working, and having no side effects does not mean it is ineffective. Some people have a strong treatment response with few or no noticeable adverse effects. Others develop immune-related side effects without having a cancer response.

Because Keytruda activates immune activity, it can sometimes cause inflammation in normal organs and tissues. Possible immune-related effects can involve the skin, intestines, lungs, liver, kidneys, thyroid, adrenal glands, pancreas, nerves, muscles, or heart. Common concerns may include rash, itching, diarrhea, tiredness, joint aches, or changes in thyroid function, but symptoms vary considerably.

New symptoms should be discussed with the treatment team rather than managed independently. In particular, patients should not start steroid medicines, anti-diarrheal medicines, supplements, or other treatments for significant new symptoms without clinical advice, unless their oncology team has already provided a specific plan. Early evaluation is important because some immune-related side effects need timely treatment or a temporary pause in immunotherapy.

Patients should continue scheduled blood tests and appointments even when they feel well. Some effects, such as changes in liver enzymes or thyroid hormone levels, may be found on routine testing before they cause noticeable symptoms.

When to seek medical care

Patients receiving Keytruda should contact their oncology team promptly about new, persistent, or worsening symptoms. This includes diarrhea, severe abdominal pain, yellowing of the skin or eyes, dark urine, a widespread rash, unusual weakness, severe headache, vision changes, increased thirst or urination, or marked changes in mood, alertness, or energy.

Urgent medical care is needed for severe shortness of breath, chest pain, fainting, confusion, coughing up blood, a high fever, severe dehydration, uncontrolled vomiting, black or bloody stools, or sudden severe weakness. These symptoms can have several causes, including infection, cancer complications, blood clots, or immune-related inflammation, and require prompt assessment.

It is helpful for patients to tell any urgent-care or emergency clinician that they are receiving pembrolizumab immunotherapy. They should also inform their oncology team as soon as possible after seeking emergency care. Carrying a treatment card or keeping the medication details available on a phone can make this easier.

When symptoms are mild but concerning, calling the oncology nurse line or clinic is often the best first step. The team can advise whether monitoring at home, an earlier appointment, blood tests, imaging, or urgent assessment is appropriate.

Questions to discuss at follow-up visits

Follow-up appointments are an opportunity to understand the treatment plan rather than simply receive scan results. Patients may ask what the latest imaging shows compared with the baseline scan, whether the result is considered response, stable disease, or progression, and whether there are any uncertain findings that need repeat imaging.

Other useful questions include: What symptoms should be reported between visits? When is the next scan planned? Are blood test results showing any possible treatment effects? What would be the next step if the cancer grows? Patients may also ask about supportive care for fatigue, nutrition, sleep, pain, emotional wellbeing, and maintaining daily activity when possible.

Family members or trusted supporters can attend appointments, take notes, or help prepare questions. This can be especially useful because cancer treatment discussions may involve unfamiliar terms and emotionally difficult decisions. Patients can ask the care team to explain results in plain language and to clarify what is known, what remains uncertain, and what will be monitored next.

Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals support international patients undergoing cancer assessment and treatment, including coordinated monitoring of immunotherapy response and side effects.

Frequently asked questions

How long does Keytruda take to show signs that it is working?

There is no single timeline. Many patients have their first response assessment after several treatment cycles, often within the first few months, but the timing depends on the cancer type and treatment plan. Some responses occur later, so the oncology team interprets results over time.

Can Keytruda be working even if a scan shows stable disease?

Yes. Stable disease means that the cancer has not grown enough to meet criteria for progression and has not shrunk enough to be called a partial response. For many advanced cancers, preventing growth for a meaningful period can be a beneficial treatment outcome.

Does a tumor getting bigger always mean Keytruda is not working?

Usually, growth on imaging suggests that cancer may be progressing, but there can be exceptions. Rarely, immune-cell activity can cause temporary enlargement or inflammation, known as pseudoprogression. The oncology team considers scan findings, symptoms, examination results, and sometimes repeat imaging before making a decision.

If I have no side effects from Keytruda, does that mean it is not effective?

No. Side effects and treatment effectiveness are not directly linked. Some people respond very well with minimal side effects, while others develop side effects without a tumor response.

Can blood tests tell whether Keytruda is working?

Blood tests can provide helpful supporting information, including organ function, blood counts, hormone levels, and sometimes tumor marker trends. However, they generally cannot confirm a treatment response by themselves. Imaging and clinical assessment remain the main methods of evaluating cancer control.

Should I stop Keytruda if I feel worse after treatment?

Patients should not stop or delay treatment on their own unless they have been given specific instructions by their oncology team. New or worsening symptoms should be reported promptly because they may be treatable side effects, cancer-related symptoms, or another health issue. The oncology team can determine whether treatment should continue, be paused, or be changed.

References

• National Cancer Institute
• American Cancer Society
• U.S. Food and Drug Administration
• European Society for Medical Oncology
• National Comprehensive Cancer Network

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.